- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-NEUR1/ NEU1/ NANH monoclonal antibody
Anti-NEUR1/ NEU1/ NANH antibody for FACS & in-vivo assay
Go to NEU1/NEU1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP0874-Ab-1/ GM-Tg-hg-MP0874-Ab-2 | Anti-Human NEU1 monoclonal antibody | Human |
| GM-Tg-rg-MP0874-Ab-1/ GM-Tg-rg-MP0874-Ab-2 | Anti-Rat NEU1 monoclonal antibody | Rat |
| GM-Tg-mg-MP0874-Ab-1/ GM-Tg-mg-MP0874-Ab-2 | Anti-Mouse NEU1 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP0874-Ab-1/ GM-Tg-cynog-MP0874-Ab-2 | Anti-Cynomolgus/ Rhesus macaque NEU1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP0874-Ab-1/ GM-Tg-felg-MP0874-Ab-2 | Anti-Feline NEU1 monoclonal antibody | Feline |
| GM-Tg-cang-MP0874-Ab-1/ GM-Tg-cang-MP0874-Ab-2 | Anti-Canine NEU1 monoclonal antibody | Canine |
| GM-Tg-bovg-MP0874-Ab-1/ GM-Tg-bovg-MP0874-Ab-2 | Anti-Bovine NEU1 monoclonal antibody | Bovine |
| GM-Tg-equg-MP0874-Ab-1/ GM-Tg-equg-MP0874-Ab-2 | Anti-Equine NEU1 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP0874-Ab-1/ GM-Tg-hg-MP0874-Ab-2; GM-Tg-rg-MP0874-Ab-1/ GM-Tg-rg-MP0874-Ab-2; GM-Tg-mg-MP0874-Ab-1/ GM-Tg-mg-MP0874-Ab-2; GM-Tg-cynog-MP0874-Ab-1/ GM-Tg-cynog-MP0874-Ab-2; GM-Tg-felg-MP0874-Ab-1/ GM-Tg-felg-MP0874-Ab-2; GM-Tg-cang-MP0874-Ab-1/ GM-Tg-cang-MP0874-Ab-2; GM-Tg-bovg-MP0874-Ab-1/ GM-Tg-bovg-MP0874-Ab-2; GM-Tg-equg-MP0874-Ab-1/ GM-Tg-equg-MP0874-Ab-2 |
| Products Name | Anti-NEU1 monoclonal antibody |
| Format | mab |
| Target Name | NEU1 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-NEU1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species NEUR1/ NEU1/ NANH VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMAP000094 | Human NEU1 Adenovirus particle |
| ORF Viral Vector | vGMAAV000260 | human NEU1 AAV particle |
| ORF Viral Vector | pGMAP000094 | Human NEU1 Adenovirus plasmid |
| ORF Viral Vector | pGMAAV000260 | human NEU1 AAV plasmid |
| ORF Viral Vector | pGMAAV000351 | Norway rat Neu1 AAV plasmid |
| ORF Viral Vector | pGMLPm003954 | mouse Neu1 Lentivirus plasmid |
| ORF Viral Vector | vGMAAV000351 | Norway rat Neu1 AAV particle |
| ORF Viral Vector | vGMLPm003954 | mouse Neu1 Lentivirus particle |
Target information
| Target ID | GM-MP0874 |
| Target Name | NEU1 |
| Gene ID | 4758,18010,24591,716740,481717,101091282,505554,100059083 |
| Gene Symbol and Synonyms | Aglp,Apl,Bat-7,Bat7,G9,Map-2,NANH,NEU,Neu-1,NEU1,SIAL1 |
| Uniprot Accession | Q99519,Q99PW3,A6BMK7 |
| Uniprot Entry Name | NEUR1_HUMAN,NEUR1_RAT,NEUR1_BOVIN |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000204386 |
| Target Classification | N/A |
The target: NEU1, gene name: NEU1, also named as NANH, NEU, SIAL1. The protein encoded by this gene is a lysosomal enzyme that cleaves terminal sialic acid residues from substrates such as glycoproteins and glycolipids. In the lysosome, this enzyme is part of a heterotrimeric complex together with beta-galactosidase and cathepsin A (the latter is also referred to as 'protective protein'). Mutations in this gene can lead to sialidosis, a lysosomal storage disease that can be type 1 (cherry red spot-myoclonus syndrome or normosomatic type), which is late-onset, or type 2 (the dysmorphic type), which occurs at an earlier age with increased severity. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
